Citigroup’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,418
| Closed | -$67.8K | – | 6481 |
|
|
2025
Q3 | $67.8K | Sell |
1,418
-8,376
| -86% | -$232K | ﹤0.01% | 4392 |
|
|
2025
Q2 | $157K | Sell |
9,794
-7,218
| -42% | -$117K | ﹤0.01% | 4175 |
|
|
2025
Q1 | $259K | Sell |
17,012
-14,001
| -45% | -$224K | ﹤0.01% | 4048 |
|
|
2024
Q4 | $629K | Buy |
31,013
+13,746
| +80% | +$346K | ﹤0.01% | 3670 |
|
|
2024
Q3 | $444K | Buy |
17,267
+11,541
| +202% | +$193K | ﹤0.01% | 3800 |
|
|
2024
Q2 | $73.6K | Sell |
5,726
-3,081
| -35% | -$49.6K | ﹤0.01% | 4365 |
|
|
2024
Q1 | $202K | Sell |
8,807
-34,291
| -80% | -$1.21M | ﹤0.01% | 4026 |
|
|
2023
Q4 | $1.13M | Buy |
43,098
+43,089
| +478,767% | +$862K | ﹤0.01% | 2724 |
|
|
2023
Q3 | $247 | Hold |
9
| – | – | ﹤0.01% | 5298 |
|
|
2023
Q2 | $268 | Sell |
9
-84,987
| -100% | -$2.17M | ﹤0.01% | 5417 |
|
|
2023
Q1 | $1.6M | Buy |
84,996
+84,973
| +369,448% | +$1.4M | ﹤0.01% | 2179 |
|
|
2022
Q4 | $231 | Sell |
23
-68
| -75% | -$1.09K | ﹤0.01% | 5586 |
|
|
2022
Q3 | $2K | Sell |
91
-140
| -61% | -$5.1K | ﹤0.01% | 5539 |
|
|
2022
Q2 | $10K | Buy |
231
+61
| +36% | +$4.81K | ﹤0.01% | 5372 |
|
|
2022
Q1 | $17K | Sell |
170
-540
| -76% | -$50.5K | ﹤0.01% | 5254 |
|
|
2021
Q4 | $109K | Buy |
710
+582
| +455% | +$86.1K | ﹤0.01% | 4689 |
|
|
2021
Q3 | $17K | Buy |
128
+77
| +151% | +$10.5K | ﹤0.01% | 5303 |
|
|
2021
Q2 | $7K | Buy |
+51
| New | +$7.81K | ﹤0.01% | 5774 |
|
Citigroup's TRML Position: Q4 2025 in Review
Citigroup sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,418 shares — an estimated $67.8K sold.
Citigroup first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $1.6M in Q1 2023. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Citigroup reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Citigroup sold 1,418 Tourmaline Bio shares in Q4 2025, an estimated $67.8K.
- Citigroup first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Citigroup's Tourmaline Bio position peaked at $1.6M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.